RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Adjuvant Trastuzumab for 6 versus 12 Months in Patients with Early Breast Cancer
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 15
SP 12
OP 13
DO 10.1177/155989771215008
UL http://mdc.sagepub.com/content/12/15/12.abstract
AB The Finland Herceptin [FinHer] trial results and concerns about cardiac toxicity with trastuzumab provided the rationale for the Trastuzumab for 6 Months or 1 Year in Treating Women with Nonmetastatic Breast Cancer That Can Be Removed by Surgery [PHARE; NCT00381901] trial. The primary objective of this noninferiority trial was to compare the effect of 6 versus 12 months of adjuvant treatment with trastuzumab on disease-free survival in patients with HER2-positive early breast cancer.